European patent awarded for Sjögren’s syndrome drug candidate
OphthaliX recently announced that its parent company, Can-Fite BioPharma, has been granted a patent by the European Patent Office for its drug candidate CF101 for treatment of Sjögren’s syndrome in Europe until 2025.
The A3 adenosine receptor agonist is a novel small molecule, orally bioavailable drug that displayed efficacy and safety during phase 2 clinical studies, according to a press release.
CF101 currently is being developed by OphthaliX for ophthalmic indications, including dry eye syndrome (phase 3 trial), glaucoma (phase 2) and uveitis (initiating phase 2), the release said. Dry eyes and mouth are common symptoms of Sjögren’s syndrome.
The patent is pursuant to a license agreement between Can-Fite and EyeFite, its wholly owned subsidiary.